

Illinois Statistics

PCSK9 Inhibitors



About PCSK9 Inhibitors

PCSK9 inhibitors are designed for patients with extremely high LDL, or “bad,” cholesterol. The drugs are approved by the Food and Drug Administration to treat:

- **Heterozygous familial hypercholesterolemia**, an inherited condition that causes high levels of LDL cholesterol
- **Clinical atherosclerotic cardiovascular disease**, such as heart attacks or strokes.

Analysis of Health Plan Coverage & Access

A national data supplier reviewed PCSK9 inhibitor claims for managed care organizations in Illinois from January 2017 through December 2017.

Key Illinois Findings



Rejection Rate:

22%



Appeals Rate:

33%



Final Rejections:

2,333

Of health plans that received at least 150 claims for PCSK9 inhibitors, the following had **the highest rates of rejections:**

- Express Scripts **40%**
- United Health Group **23%**
- CVS Health **31%**
- Health Care Services Corp. HCSC **21%**

The following had **the lowest rates of rejection:**

- Aetna **10%**
- Humana Health Plan **7%**



The following table details claims data for the Illinois managed care organizations that received at least 150 claims for PCSK9 inhibitors.

Managed Care Organization	Rejection %	Total Claims	Rejections
Express Scripts	40%	340	137
CVS Health	31%	812	248
United Health Group	23%	1,712	397
Health Care Services Corporation HCSC	21%	2,041	430
Rite Aid	20%	178	36
Illinois State Employees	18%	204	36
Cigna Healthcare	16%	533	87
Aetna	10%	1,127	114
Humana Health Plan	7%	1,676	125

Data source: National data supplier; Medicare, Medicaid, Medicaid managed care, and commercial plans; January-December 2017.



The Institute for Patient Access is a physician led nonprofit 501(c)(3) research organization promoting the benefits of the physician-patient relationship in the provision of quality healthcare.

